Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Cash & Equivalents (2016 - 2025)

Bio-Techne (TECH) has 17 years of Cash & Equivalents data on record, last reported at $172.9 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 2.63% year-over-year to $172.9 million; the TTM value through Dec 2025 reached $172.9 million, down 2.63%, while the annual FY2025 figure was $162.2 million, 6.85% up from the prior year.
  • Cash & Equivalents reached $172.9 million in Q4 2025 per TECH's latest filing, up from $145.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $211.8 million in Q4 2021 and bottomed at $127.3 million in Q1 2023.
  • Average Cash & Equivalents over 5 years is $166.0 million, with a median of $165.0 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 77.49% in 2021, then dropped 22.7% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $211.8 million in 2021, then decreased by 22.26% to $164.7 million in 2022, then decreased by 20.98% to $130.1 million in 2023, then surged by 36.44% to $177.5 million in 2024, then dropped by 2.63% to $172.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $172.9 million in Q4 2025, $145.0 million in Q3 2025, and $162.2 million in Q2 2025.